$EXEL - On our trading list with news today or analyst comments with our opinion & trade ideas. Exelixis price target raised to $33 from $30 at Piper Sandler after drug data.Exelixis price target raised to $33 from $30 at Piper SandlerPiper Sandler analyst Edward Tenthoff raised the firm's price target on Exelixis ($EXEL) to $33 from $30 and keeps an Overweight rating on the shares after the company and partner Bristol-Myers Squibb ($BMY) presented full Phase III CheckMate-9ER data for Cabometyx plus Nivolumab in first-line renal cell carcinoma. Key opinion leaders sees potential for Cabometyx plus Nivolumab to dominate in first-line renal cell carcinoma, Tenthoff tells investors in a research note.Our Take: This biotech makes money and continues R&D, in this case with partner Bristol-Myers. We would add on any dips and take some profits on peaks. $EXEL, Exelixis, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try. Trade Try2BeFunded today! .